Search results for: Peter J. Neumann
Filter search results
What is the future of health economics?
1 May 2023
…can we best to align the incentives health system goals — those are the bigger questions.” It’s a black box that we don’t often open up Peter Smith, Emeritus Professor…
OHE’s contribution to health economics
1 May 2023
…in that OHE has played an important role.” Peter Smith, Emeritus Professor of Health Policy at Imperial College London, acknowledges the OHE’s respected ‘middleman’ role between the pharmaceutical industry and…
New Publication: Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers
25 September 2015
…the full study here. Reference: Garrison, L., Carlson, J., Bajaj, P., Towse, A., Neumann, P., Sullivan, S., Westrich, K. and Dubois, R., 2015. Private Sector Risk-Sharing Agreements in the United…
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
…Economics Approach: An ISPOR Special Task Force Report [4] Value in Health, Vol. 21, Issue 2, p140–145DOI: https://doi.org/10.1016/j.jval.2017.12.008; Published in February 2018. Garrison, L.P., Neumann, P.J., Wilkie, R.J., Basu, A., Danzon,…
25 Years of the Cost Effectiveness Acceptability Curve
30 December 2019
…Prosser, L.A., Salomon, J.A., Sculpher, M.J., Trikalinos, T.A., Russell, L.B., Siegel, J.E. and Ganiats, T.G., 2016. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
…The Watkins and Tsiao response is available in the same issue as open access here. Related Research Garrison LP, Neumann, PJ, Willke, RJ, et al., 2018. A health economics approach to U.S. value…
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
…Health Economics. Sanders, G.D., Neumann, P.J., Basu, A., Brock, D.W., Feeny, D., Krahn, M., Kuntz, K.M., Meltzer, D.O., Owens, D.K., Prosser, L.A., Salomon, J.A., Sculpher, M.J., Trikalinos, T.A., Russell, L.B.,…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…Neumann, P.J., Willke, R.J. et al. (2018). A health economics approach to U.S. value assessment frameworks—summary and recommendations of the ISPOR special task force report [7]. Value in Health; 21:161–5….
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…Economic Evaluations of Gene Therapies and Their Application in Literature. Value in Health. 2020;23(9):1268-1280. doi:10.1016/j.jval.2020.04.1833 Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic Considerations in Applying a General Economic…